Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Exenatide extended-release
Drug: LY2944876
Drug: Placebo
Drug: Metformin

First Posted Date: 2014-04-22

Last Posted Date: 2021-05-27

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 420

Registration Number: NCT02119819

Locations: 🇺🇸
Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States
🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania
🇵🇷
Manati Medical Center, Manati, Puerto Rico

and more 31 locations

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY2409021
Drug: Placebo
Drug: Sitagliptin
Drug: Metformin
Drug: Sulfonylurea

First Posted Date: 2014-04-10

Last Posted Date: 2019-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 174

Registration Number: NCT02111096

Locations: 🇺🇸
Midwest CRC, Crystal Lake, Illinois, United States
🇺🇸
Iderc, P.L.C., Des Moines, Iowa, United States
🇺🇸
Cotton O'Neil Clinic, Topeka, Kansas, United States

and more 27 locations

Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 187004
Drug: metformin

First Posted Date: 2014-04-10

Last Posted Date: 2016-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02109679

Locations: 🇩🇪
1307.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: LY2409021
Drug: Metformin

First Posted Date: 2014-03-19

Last Posted Date: 2018-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 270

Registration Number: NCT02091362

Locations: 🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸
Cedar-Crosse Research Center, Chicago, Illinois, United States
🇺🇸
National Research Institute, Los Angeles, California, United States

and more 15 locations